JeffreyJosephIshizukaMDDphil

PubMed

• Immunotherapy utilization in stage IIIA melanoma: less may be more.
  Frey, A., Clune, J., Kerekes, D., Khan, S., Tran, T., Kluger, H., Ariyan, S., Sznol, M., Ishizuka, J., Olino, K.> ;Frontiers in Oncology. 2024 Jan 1
• 3 citations
  Causal identification of single-cell experimental perturbation effects with CINEMA-OT.
  Mingze Dong, Bao Wang, Jessica Wei, Antonio H de O Fonseca, Curtis J Perry, Alexander Frey, Feriel Ouerghi, Ellen F Foxman, Jeffrey J Ishizuka, David van Dijk, Rahul M...> ;Nature Methods. 2023 Nov 1
• Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.
  Brooke Horowitch, Daniel Y Lee, Min Ding, Sandra Martinez-Morilla, Thazin Nwe Aung, Feriel Ouerghi, Xueting Wang, Wei Wei, William Damsky, Mario Sznol, Harriet Kluger,...> ;Clinical Cancer Research. 2023 Aug 1
• 20 citations
  PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.
  Natalie B Collins, Rose Al Abosy, Brian C Miller, Kevin Bi, Qihong Zhao, Michael Quigley, Jeffrey J Ishizuka, Kathleen B Yates, Hans W Pope, Robert T Manguso, Yashaswi...> ;Journal for Immunotherapy of Cancer. 2022 Mar 1
• 24 citations
  Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
  Gabriel K. Griffin, Jason L. Weirather, Margaretha G.M. Roemer, Mikel Lipschitz, Alyssa Kelley, Pei Hsuan Chen, Daniel Gusenleitner, Erin Jeter, Christine Pak, Evisa G...> ;Blood. 2021 Mar 11
• 35 citations
  Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
  Shilpa Grover, Michael Dougan, Kevin Tyan, Anita Giobbie-Hurder, Steven M. Blum, Jeffrey J. Ishizuka, Taha Qazi, Rawad Elias, Kruti Vora, Alex B. Ruan, William Martin-...> ;Cancer. 2020 Aug 15
• 10 citations
  Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
  Brian C. Miller, Debattama R. Sen, Rose Al Abosy, Kevin Bi, Yamini V. Virkud, Martin W. LaFleur, Kathleen B. Yates, Ana Lako, Kristen Felt, Girish S. Naik, Michael Man...> ;Nature Immunology. 2019 Nov 1
• 125 citations
  Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
  Panagiotis A. Konstantinopoulos, Weixiu Luo, Joyce F. Liu, Doga Gulhan, Carolyn N. Krasner, Jeffrey J. Ishizuka, Allison Gockley, Mary K. Buss, Whitfield B. Growdon, H...> ;Journal of Clinical Oncology. 2019 Aug 28
• 956 citations
  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
  Brian C. Miller, Debattama R. Sen, Rose Al Abosy, Kevin Bi, Yamini V. Virkud, Martin W. LaFleur, Kathleen B. Yates, Ana Lako, Kristen Felt, Girish S. Naik, Michael Man...> ;Nature Immunology. 2019 Feb 18
• 376 citations
  Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.
  Jeffrey J. Ishizuka, Robert T. Manguso, Collins K. Cheruiyot, Kevin Bi, Arpit Panda, Arvin Iracheta-Vellve, Brian C. Miller, Peter P. Du, Kathleen B. Yates, Juan Dubro...> ;Nature. 2019 Jan 1
• Join now to see all